RxDoctor Payments Data

David Nye, DO

Vascular Surgery · Peoria, AZNPI 1558623793

Payments from drug & device makers

What this record shows

This record is dominated by grants: $5,000 of the $7,425 with a category attached, or 67.3%. Medtronic accounts for 70.4% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $6,290 and has fallen 96.6% since, to $214 in 2025. That places this record below the midpoint for vascular surgery clinicians in AZ, where the typical reported total is $6,983.

$7,425in general payments, 2019–2025

Across 73 payments — averaging $101.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Silk Road Medical, Inc.$998
  • Cordis US CORP.$296
  • W. L. Gore & Associates, Inc.$130
  • Philips North America LLC$122
  • Johnson & Johnson$97
  • plus $554 from 15 others

What the payments were for

  • Grants$5,00067%
  • Travel & lodging$78011%
  • Food & beverage$1,64622%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,425 in reported general payments places this provider in the 50th percentile of 105 vascular surgery providers in Arizona.

See all vascular surgery providers in Arizona

Medicare billing

Part B allowed, 2024
$33,801,613
Medicare patients
943
Services billed
24,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban19$17,892
EliquisApixaban12$12,019
ClopidogrelClopidogrel Bisulfate76$777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$97$17,89219 claims
PfizerEliquis$61$12,01912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 105 vascular surgery providers in Arizona.

Other vascular surgery in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →